Please use this identifier to cite or link to this item:
Title: Impact of Diabetes on 10‐Year Outcomes Following ST‐Segment–Elevation Myocardial Infarction: Insights From the EXAMINATION‐EXTEND Trial
Author: Spione, Francesco
Arevalos, Victor
Gabani, Rami
Ortega Paz, Luis
Gomez Lara, Josep
Jimenez Diaz, Victor
Jimenez, Marcelo
Jiménez Quevedo, Pilar
Diletti, Roberto
Pineda, Javier
Campo, Gianluca
Di Silvestro, Antonio
Maristany, Jaume
Flores, Xacobe
Oyarzabal, Loreto
Bastos Fernandez, Guillermo
Iñiguez, Andrés
Serra, Antonio
Escaned, Javier
Ielasi, Alfonso
Tespili, Maurizio
Lenzen, Mattie
Gonzalo, Nieves
Bordes, Pascual
Tebaldi, Matteo
Biscaglia, Simone
Al‐Shaibani, Soheil
Romaguera, Rafael
Gomez Hospital, Joan Antoni
Rodes Cabau, Josep
Serruys, P. W.
Sabaté, Manel
Brugaletta, Salvatore
Keywords: Diabetis
Infart de miocardi
Assaigs clínics
Myocardial infarction
Clinical trials
Issue Date: 6-Dec-2022
Publisher: Ovid Technologies (Wolters Kluwer Health)
Abstract: BACKGROUND: Long-term outcomes of ST-segment-elevation myocardial infarction in patients with diabetes have been barely investigated. The objective of this analysis from the EXAMINATION-EXTEND (10-Years Follow-Up of the EXAMINATION trial) trial was to compare 10-year outcomes of patients with ST-segment-elevation myocardial infarction with and without diabetes. METHODS AND RESULTS: Of the study population, 258 patients had diabetes and 1240 did not. The primary end point was patient-oriented composite end point of all-cause death, any myocardial infarction, or any revascularization. Secondary end points were the individual components of the primary combined end point, cardiac death, target vessel myocardial infarction, target lesion revascularization, and stent thrombosis. All end points were adjusted for potential confounders. At 10 years, patients with diabetes showed a higher incidence of patient-oriented composite end point compared with those without (46.5% versus 33.0%; adjusted hazard ratio [HR], 1.31 [95% CI, 1.05-1.61]; P=0.016) mainly driven by a higher incidence of any revascularization (24.4% versus 16.6%; adjusted HR, 1.61 [95% CI, 1.19-2.17]; P=0.002). Specifically, patients with diabetes had a higher incidence of any revascularization during the first 5 years of follow-up (20.2% versus 12.8%; adjusted HR, 1.57 [95% CI, 1.13-2.19]; P=0.007) compared with those without diabetes. No statistically significant differences were found with respect to the other end points. CONCLUSIONS: Patients with ST-segment-elevation myocardial infarction who had diabetes had worse clinical outcome at 10 years compared with those without diabetes, mainly driven by a higher incidence of any revascularizations in the first 5 years.
Note: Reproducció del document publicat a:
It is part of: Journal of the American Heart Association, 2022, vol. 11, num. 23, p. e025885
Related resource:
ISSN: 2047-9980
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
JAHA.122.025885.pdf1.07 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons